Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

After rejection, FDA approves Telix's Pixclara, the first FET-PET imaging drug for brain cancer

15 September 2026 · By · Wire by Fusion42

Published

15 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 16 September 2026 · Fusion42 review

The FDA has approved Telix Pharmaceuticals' Pixclara, the first FET-PET imaging drug for glioma brain tumors, following a previous rejection that requested more clinical evidence. The drug improves diagnostic certainty and treatment planning for glioma patients in the U.S.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 14 Sep 2026 and 15 Sep 2026.

◆ ◆ The Wire takeaway

You have a new regulatory precedent making brain cancer imaging drugs viable in the U.S. market. This opens field diagnostics and treatment planning products to faster approval routes and adoption.

◆ Coverage

2 sources · first reported 14 Sep 2026 · latest 15 Sep 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvalbrain-cancerimaging-drugsgliomaTelix